Abstract
Gluten ataxia, a type of cerebellar ataxia caused by exposure to gluten in sensitive patients, has been considered common in the USA and Europe, and rare in Asia. We measured anti-deamidated gliadin peptide (DGP) antibody levels in 49 patients with cerebellar ataxia, excluding those with multiple system atrophy, hereditary spinocerebellar ataxia, or cancer, as well as those who were receiving oral administration of phenytoin. Anti-DGP antibody was positive in eight (16.3 %) patients, five of these patients were positive only for IgA, one was positive for both IgG and IgA, and two were positive only for IgG antibody. Intravenous immunoglobulin was administered to five of the eight patients, and was markedly effective in one, moderately effective in two, and ineffective in two. Steroid therapy was administered to four patients, but none had an apparent response. Ataxia symptoms improved in one patient treated with a gluten-free diet only. Although it had been thought to be extremely rare in Asia, we speculate that more than 10 % of cerebellar ataxia patients in Japan currently have gluten ataxia; therefore, measuring anti-DGP antibody or anti-gliadin antibody in cerebellar ataxia patients in Asia is important.
Similar content being viewed by others
References
Ford RP. The gluten syndrome: a neurological disease. Med Hypotheses. 2009;73:438–40.
Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoimmune diseases. Mov Disord. 2012;27:935–46.
Hadjivassiliou M, Boscolo S, Davies-Jones GA, Grünewald RA, Not T, Sanders DS, et al. The humoral response in the pathogenesis of gluten ataxia. Neurology. 2002;58:1221–6.
Nanri K, Okita M, Takeguchi M, Taguchi T, Ishiko T, Saito H, et al. Intravenous immunoglobulin therapy for autoantibody-positive cerebellar ataxia. Intern Med. 2009;48:783–90.
Bürk K, Bösch S, Müller CA, Melms A, Zühlke C, Stern M, et al. Sporadic cerebellar ataxia associated with gluten sensitivity. Brain. 2001;124:1013–9.
Ihara M, Makino F, Sawada H, Mezaki T, Mizutani K, Nakase H, et al. Gluten sensitivity in Japanese patients with adult-onset cerebellar ataxia. Intern Med. 2006;45:135–40.
Nanri K, Shibuya M, Taguchi T, Hasegawa A, Tanaka N. Selective loss of Purkinje cells in a patient with anti-gliadin-antibody-positive autoimmune cerebellar ataxia. Diagn Pathol. 2011;6:14.
Nanri K, Otsuka T, Takeguchi M, Taguchi T, Ishiko T, Mitoma H, et al. A case of anti-gliadin-antibody-positive cerebellar ataxia effectively treated with intravenous immunoglobulin in which voxel-based morphometry and FineSRT were diagnostically useful. Rinsho Shinkeigaku. 2009;49:37–42.
Tanaka N, Ohtake H, Ito S, Niiyama K, Nanri K. A case of anti-TPO/gliadin antibody-positive cerebellar atrophy that responded to intravenous immunoglobulin therapy begun 16 years after onset. Rinsho Shinkeigaku. 2012;52:351–5.
Hadjivassiliou M, Davies-Jones GA, Sanders DS, Grünewald RA. Dietary treatment of gluten ataxia. J Neurol Neurosurg Psychiatry. 2003;74:1221–4.
Bürk K, Melms A, Schulz JB, Dichgans J. Effectiveness of IVIg therapy in cerebellar ataxia associated gluten sensitivity. Ann Neurol. 2001;50:827–8.
Souayah N, Chin RL, Brannagan TH, Latov N, Green PHR, Kokoszka A, et al. Effect of intravenous immunoglobulin on cerebellar ataxia and neuropathic pain associated with celiac disease. Eur J Neurol. 2008;15:1300–3.
Acknowledgments
The authors express their gratitude to Mr. C. W. P. Reynolds, associated with the Department of International Medical Communications of Tokyo Medical University, for his careful revision of the English of this paper.
Funding
None of the authors have any external sources of funding to report.
Competing Interests
None of the authors have any conflicts of interest to report.
Patient Consent
Informed consent was obtained from all patients included in this report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nanri, K., Mitoma, H., Ihara, M. et al. Gluten Ataxia in Japan. Cerebellum 13, 623–627 (2014). https://doi.org/10.1007/s12311-014-0582-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12311-014-0582-3